<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Obesity: Genetic contribution and pathophysiology</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Obesity: Genetic contribution and pathophysiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Obesity: Genetic contribution and pathophysiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leigh Perreault, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Rosenbaum, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Xavier Pi-Sunyer, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1124819458"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Obesity is a complex disease reflecting the interactions of environmental influences (eg, more calorically dense food and increasingly sedentary lifestyles) with multiple known obesity-risk genetic allelic variants of variable effect sizes [<a href="#rid1">1-4</a>]. These includes severe, usually early-onset obesity caused by single-gene mutations with distinctive phenotypes, the more common gene mutations associated with increased risks of weight gain but an overall smaller effect size, and obesity caused by various diseases in subjects in whom obesity would otherwise not occur [<a href="#rid1">1</a>]. The physiology and pathophysiology of obesity reflect the interactions of genes predisposing to or opposing weight gain and its comorbidities with an increasingly obesogenic environment  (<a class="graphic graphic_figure graphicRef130699" href="/d/graphic/130699.html" rel="external">figure 1</a>).</p><p>This topic will review the types of obesity caused by specific allelic variants, the genetic susceptibility to obesity, and their contributions to the pathogenetic mechanisms that regulate total body fat content and regional fat distribution.</p><p>An additional discussion of causes of and contributors to obesity in adults can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/5377.html" rel="external">"Obesity in adults: Etiologies and risk factors"</a>.)</p><p class="headingAnchor" id="H930467506"><span class="h1">HERITABLE FACTORS</span><span class="headingEndMark"> — </span>Studies of adiposity between twins, adoptees, and their parents (biological versus adoptive), and within families, all suggest the existence of genetic factors in humans with obesity [<a href="#rid5">5,6</a>]. The heritability of adiposity estimated from twin studies is high, ranging from 40 to 75 percent [<a href="#rid7">7</a>], with only slightly lower values in twins raised apart compared with those raised together. Similarly, in adoptees, the body mass index (BMI) correlates better with that of their biologic parents than their adoptive parents. Over 500 adiposity- or adiposity-related trait genetic loci have been identified. In addition to BMI, responses to overfeeding and underfeeding, energy expenditure, food choices, hunger, and satiation have all been shown to be significantly heritable [<a href="#rid7">7-12</a>].</p><p class="headingAnchor" id="H1161052685"><span class="h2">Common (multifactorial) obesity</span><span class="headingEndMark"> — </span>Common (multifactorial) obesity is polygenic and reflects the cumulative interactions of multiple genetic loci favoring body adiposity with the environment. Body adiposity is heritable, but the genes that contribute to the more common forms of obesity have been a challenge to identify. However, genomic analyses have yielded information on allelic variants associated with obesity.</p><p class="bulletIndent1"><span class="glyph">●</span>In a combined meta-analysis including 82 genome-wide association studies (GWAS) and 43 metabochip studies in nearly 340,000 individuals, 97 loci associated with BMI were identified [<a href="#rid13">13</a>]. These loci account for approximately 2.7 percent of the variation in BMI; the authors estimate that as much as 21 percent of BMI variation can be accounted for by the most common allelic variants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over 50 genetic loci have been associated with waist-to-hip ratios (adjusted for BMI) and demonstrate sexual dimorphism, which is often expressed in adipose tissue [<a href="#rid14">14-22</a>]. The relationship of BMI with a number of genes is shown in the figure  (<a class="graphic graphic_figure graphicRef87759" href="/d/graphic/87759.html" rel="external">figure 2</a>). In general, BMI-associated loci tend to be related to energy homeostatic pathways in the brain, while body fat-distribution associated loci tend to involve pathways regulating adipocyte biology [<a href="#rid7">7</a>].</p><p></p><p>Environmental factors appear to modify the genetic associations with BMI. In an observational study of almost 9000 adults aged ≥50 years, the magnitude of association between BMI and a polygenic risk score (a weighted sum of 29 single nucleotide polymorphisms [SNPs]) was higher in more recent birth cohorts compared with the earlier birth cohorts [<a href="#rid23">23</a>]. The difference is believed to be related to the duration of exposure to an increasingly "obesogenic" environment: the lifestyle transformation that began in the late 1970s, such as dietary changes with an increased food and sugar-sweetened beverage intake and reduction in regular physical activity. Younger cohorts were exposed to this environment at an earlier age, while older cohorts were not exposed until later in life.</p><p class="headingAnchor" id="H2058738121"><span class="h2">Fat mass and obesity (FTO) gene variants</span><span class="headingEndMark"> — </span>Among the genes identified by GWAS, the <em>FTO</em> (fat mass- and obesity-associated) gene on chromosome 16 has the strongest genetic association with obesity [<a href="#rid15">15,24</a>]. For example, SNP variants in the first intron of <em>FTO</em> on 16q12.2 are noteworthy among common obesity-risk alleles for their frequency (approximately 70 percent of all people are heterozygous or homozygous for an obesity-risk <em>FTO</em> SNP) and potency (1.3 to 1.7 times increased obesity risk in adults) [<a href="#rid15">15</a>]. A specific variant predisposes to type 2 diabetes through an effect on BMI [<a href="#rid15">15</a>], while others may independently increase diabetes risk via effects in other tissues [<a href="#rid25">25</a>]. In one study, among 13 European cohorts, 16 percent of adults were homozygous for the risk allele and weighed, on average, 3 kg more than those without the risk allele [<a href="#rid15">15</a>]. Both studies found an approximate 1.5-fold increase in the risk of obesity with the inherited risk genotype, which was seen in both children and adults. Several reports suggest that the at-risk <em>FTO</em> haplotype may account for up to 15 to 20 percent of common obesity [<a href="#rid15">15,24,26</a>].</p><p>The mechanisms of the association between <em>FTO</em> variants and obesity are unclear. Most studies indicate that the primary effects of obesity-risk <em>FTO </em>SNPs are to increase energy intake [<a href="#rid27">27</a>]. However, a noncoding causal variant in <em>FTO</em> has been identified that changes the function of adipocytes from energy utilization (beige fat) to energy storage (white fat) and decreases mitochondrial thermogenesis fivefold [<a href="#rid28">28</a>]. In studies using genetically engineered mice, when the effect of this variant was blocked, thermogenesis increased and no weight occurred despite consumption of a high-fat diet. In human adipocytes, blocking the gene's effect also increased energy utilization. This observation has important implications for potential new anti-obesity drugs. FTO is also an example of genetic and environmental interactions; SNPs’ effects on adiposity is influenced by physical activity as well as dietary macronutrient composition [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3994812260"><span class="h1">MONOGENIC FORMS OF OBESITY</span><span class="headingEndMark"> — </span>Early-onset severe obesity is more likely be predominantly genetic in origin  (<a class="graphic graphic_table graphicRef70658" href="/d/graphic/70658.html" rel="external">table 1</a>). In particular, the monogenic forms of obesity should be considered in the evaluation of adults or children with a lifetime history of obesity  (<a class="graphic graphic_table graphicRef82307" href="/d/graphic/82307.html" rel="external">table 2</a>). In such patients, the identification of certain genetic mutations may be significant, as targeted therapies may be appropriate as a part of treatment. As an example, <a class="drug drug_general" data-topicid="130245" href="/d/drug information/130245.html" rel="external">setmelanotide</a>, a melanocortin 4 receptor agonist is available for the treatment of obesity due to proopiomelanocortin (<em>POMC</em>), proprotein convertase subtilisin/kexin type 1 (<em>PCSK1</em>), leptin receptor gene (<em>LEPR</em>) deficiency, or Bardet-Biedl syndrome confirmed by genetic testing [<a href="#rid30">30</a>]. (See <a class="local">'Leptin'</a> below and <a class="local">'Prohormone convertase (1/3)'</a> below and <a class="local">'Proopiomelanocortin'</a> below and <a class="local">'Bardet-Biedl syndrome'</a> below.) </p><p class="headingAnchor" id="H3331310712"><span class="h2">Prader-Willi syndrome</span><span class="headingEndMark"> — </span>The Prader-Willi syndrome is a neurodegenerative disorder that is caused by genetic abnormalities of the long arm of chromosome 15 (q11-13). The majority of patients have a deletion of paternal DNA in this region; most of the remainder have two copies of maternal chromosome 15 (uniparental disomy) [<a href="#rid31">31,32</a>]. The key genetic material usually lacking is the <em>SNRPN </em>gene, which codes for a small nuclear ribonucleoprotein thought to be involved in imprinting genes from both parents. (See  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16647.html" rel="external">"Genomic disorders: An overview", section on 'Disease mechanisms'</a> and  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'</a>.)</p><p>Affected infants have poor muscle tone and feed poorly at birth. As they grow, their appetite becomes voracious and they go on to develop obesity, behavior problems (eg, irritability, tantrums), delayed development, short stature, and, later, hypogonadotropic hypogonadism. The clinical presentation, diagnosis, and management of patients with Prader-Willi syndrome is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5864.html" rel="external">"Prader-Willi syndrome: Management"</a>.)</p><p class="headingAnchor" id="H2744130704"><span class="h2">Bardet-Biedl syndrome</span><span class="headingEndMark"> — </span>The Bardet-Biedl syndrome is an autosomal recessive disorder characterized by obesity and several other abnormalities, including microorchidism in men, intellectual disability, retinal dystrophy, polydactyly, renal malformations (particularly calyceal abnormalities), and polyuria and polydipsia [<a href="#rid33">33</a>].</p><p>Mutations in at least 15 genes have been described in patients with this syndrome [<a href="#rid34">34</a>]. Disordered function of the primary cilia may be a fundamental defect in this syndrome [<a href="#rid35">35</a>]. <a class="drug drug_general" data-topicid="130245" href="/d/drug information/130245.html" rel="external">Setmelanotide</a>, a melanocortin receptor agonist, is available for the management of obesity in individuals ≥6 years of age with Bardet-Biedl syndrome [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2738047776"><span class="h2">Leptin</span><span class="headingEndMark"> — </span>Leptin is a peptide hormone that reflects both energy stores (predominantly fat) and energy balance (weight loss or maintenance). It is produced in fat cells, the placenta, and, to a lesser degree, the gut [<a href="#rid36">36</a>]. Leptin binds to leptin receptors on the surface of neurons in the hypothalamus to modulate food intake and energy balance. Sensitivity to leptin is modulated by changes in energy balance (exogenous leptin is less effective during weight loss than maintenance of reduced weight) and energy stores (exogenous leptin is less effective at usual weight than during maintenance of reduced weight). </p><p>The LEP gene codes for leptin [<a href="#rid37">37</a>]. Mutations of the LEP gene or its receptor are rare causes of severe, early onset obesity [<a href="#rid2">2,38,39</a>]. These congenital disorders of leptin deficiency and dysfunction are autosomal recessive conditions characterized by severe, early onset obesity, hyperphagia, hypometabolism, delayed puberty, and glucose intolerance [<a href="#rid39">39</a>].</p><p>Pathogenic variants of the LEP gene can cause obesity disorders in humans via several mechanisms. </p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal recessive loss-of-function mutations in the LEP gene can cause a lack of leptin synthesis or secretion. In these disorders, circulating leptin levels are low to undetectable. Over 20 distinct variants have been identified [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another family of mutations in the LEP gene results in a leptin variant that either fails to bind to the leptin receptor (LEPR) or binds abnormally and acts as a competitive antagonist. In these conditions, circulating leptin levels are high. Case reports suggest that treating these patients with supraphysiologic doses of leptin can overcome this competitive antagonism and result in resumption of changes in eating behavior and weight loss [<a href="#rid39">39,41</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in the LEPR gene can produce leptin receptors that either do not bind leptin or do not signal normally. In these conditions, circulating leptin levels are high but physiologically appropriate for the patient's level of obesity [<a href="#rid42">42,43</a>]. Over 35 variants of the leptin receptor gene have been described. </p><p></p><p class="headingAnchor" id="H3108603251"><span class="h2">Prohormone convertase (1/3)</span><span class="headingEndMark"> — </span>Congenital deficiency of the <em>PCSK1</em> gene, which encodes proprotein convertase 1/3, causes a severe multihormonal disorder marked by early-onset obesity. A systematic review from the Human Genome Epidemiology (HuGE) project demonstrated that three single nucleotide polymorphisms (SNPs rs6232, rs6234, and rs6235) in <em>PCSK1</em> are associated with obesity in some populations [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3638439266"><span class="h2">Melanocortin-4 receptor</span><span class="headingEndMark"> — </span>Congenital deficiency of melanocortin-4 receptor (MC4R) is associated with early-onset obesity and taller-than-average height. Evidence from one patient with a homozygous mutation in the receptor suggests that MC4R mediates most of the anorectic effects of leptin in early childhood but not the effect of leptin on linear growth and other endocrine axes [<a href="#rid45">45,46</a>]. In a genome-wide association study (GWAS) of 16,000 individuals (and confirmed in additional populations), common variants near the MC4R were associated with increasing body mass index (BMI) in both children and adults [<a href="#rid16">16</a>]. Heterozygous mutations in this gene are reported to be the most common monogenic cause of severe obesity in childhood in some [<a href="#rid43">43,45</a>] but not all [<a href="#rid47">47</a>] studies.</p><p class="headingAnchor" id="H1348135128"><span class="h2">Proopiomelanocortin</span><span class="headingEndMark"> — </span>Melanocyte-stimulating hormone (MSH) transmits the anorexic effect of leptin through the MC4R (see <a class="local">'Melanocortin-4 receptor'</a> above). Individuals with homozygous or compound heterozygous mutations in the gene encoding proopiomelanocortin (<em>POMC</em>) present with adrenal crisis in neonatal life due to corticotropin (ACTH) deficiency. ACTH is produced from POMC in the hypothalamus, as is alpha-MSH, an important factor for reducing food intake [<a href="#rid48">48</a>]. Therefore, patients with these <em>POMC</em> mutations also have early-onset obesity due to severe hyperphagia. <a class="drug drug_general" data-topicid="130245" href="/d/drug information/130245.html" rel="external">Setmelanotide</a>, a melanocortin receptor agonist, have been tested in patients with POMC deficiency with some success [<a href="#rid49">49,50</a>] and is available for treatment [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H1245833301"><span class="h2">GNAS</span><span class="headingEndMark"> — </span>Certain mutations in GNAS (guanine nucleotide binding protein [G-protein], alpha stimulating) are associated with Albright's hereditary osteodystrophy (ie, Type 1 pseudohypoparathyroidism), characterized by early-onset obesity, with or without developmental delay, short stature, brachydactyly, subcutaneous ossifications, pseudohypoparathyroidism (hypocalcemia, PTH resistance), and thyrotropin resistance (elevated thyroid-stimulating hormone [TSH] with normal or low free thyroxine [fT4]). Obesity is likely mediated by disrupted MC4R signaling  (<a class="graphic graphic_table graphicRef70658" href="/d/graphic/70658.html" rel="external">table 1</a>) [<a href="#rid53">53</a>]. This is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children", section on 'Type 1 PHP'</a>.)</p><p class="headingAnchor" id="H349762897"><span class="h2">Other</span><span class="headingEndMark"> — </span>Additional genes can also play a significant role in the development of obesity. Two of these are brain-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor tropomyosin-related kinase B (TrkB). Children with mutations have severe hyperphagia and obesity, impaired short-term memory, hyperactivity, and learning disability [<a href="#rid54">54</a>]. Patients with Wilms tumor-aniridia syndrome (WAGR) have a subset of deletions on chromosome 11p.12, encompassing the BDNF locus. These patients also have early-onset obesity [<a href="#rid55">55</a>] (see  <a class="medical medical_review" href="/d/html/6249.html" rel="external">"Presentation, diagnosis, and staging of Wilms tumor", section on 'WAGR syndrome'</a>). The second gene is single-minded 1 (<em>SIM1</em>) [<a href="#rid56">56</a>]; patients deficient in SIM1 are hyperphagic with evidence of autonomic dysfunction, which is also seen in MC4R deficiency, suggesting that some aspects of the clinical phenotype can be explained by altered melanocortin signaling. Carriers of the <em>SIM1</em> mutation may have speech and language delay and exhibit neurobehavioral abnormalities including autistic types of behavior. These features can be seen in Prader-Willi syndrome but are not recognized features of MC4R deficiency.</p><p class="headingAnchor" id="H2993585007"><span class="h1">PHYSIOLOGY AND PATHOPHYSIOLOGY OF OBESITY</span></p><p class="headingAnchor" id="H1834034692"><span class="h2">Genetics and physiology</span><span class="headingEndMark"> — </span>Almost every aspect of the behaviors and the metabolism affecting weight gain, and the responses to negative and positive energy balance, are heritable. Various assessments of eating behavior (food choice, caloric intake, etc) have estimated the genetic contribution to the variation in energy intake at between 20 and 50 percent [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1053048411"><span class="h2">The regulation of body weight</span><span class="headingEndMark"> — </span>Energy intake and expenditure are remarkably coupled to regulate body weight in the face of wide daily fluctuations in diet and physical activity. This “coupling,” which opposes ongoing weight perturbation, is evident in the surprisingly small, average yearly weight gain by adults in the United States (0.5 to 1.5 kg/year, or about 4000 kcal of stored energy). Since adults in the United States consume, on average, approximately 900,000 kcal/year, this small weight gain represents a (largely involuntary) positive energy balance of approximately 0.4 percent. What many consider “normal” age-related weight gain actually reflects a well-coordinated system to prevent major changes in energy stores. If energy intake and output were not coupled, then increasing or decreasing energy expenditure by as little as 50 kcal/day (roughly equivalent to the energy expended in walking 0.5 to 0.75 km) without changing energy intake would result in a net energy imbalance of 25,000 kcal (about 4.5 kg of body weight) over one year.</p><p class="headingAnchor" id="H2756776340"><span class="h3">Resistance to weight loss and maintenance of reduced weight</span><span class="headingEndMark"> — </span>Among individuals with overweight or obesity, the likelihood of losing and sustaining greater than 10 percent of body weight (without bariatric surgery) has remained at about 15 percent over the past several decades [<a href="#rid58">58</a>]. The metabolic, neuroendocrine, autonomic, and behavioral responses to active weight loss and to maintenance of weight loss are distinct.</p><p>In most studies, lifestyle, pharmacologic, or surgical treatments of obesity result in weight loss of varying slope for about six to nine months, followed by a plateau period, with a subsequent period of weight regain [<a href="#rid59">59-64</a>]. This observation that weight loss generally occurs over a limited period of time, whereas maintenance of reduced weight will require, in most cases, a lifetime of diligent attention, suggests that efforts to lose more weight should be concentrated on the relatively brief weight loss period. As described below, the “normal” coupling of energy expenditure and intake at the usual weight (eg, increased energy expenditure leads to increased energy intake) is lost after weight loss; such individuals become both hypometabolic and hyperphagic. Therefore, efforts to sustain weight loss should be designed to reverse or counterbalance the disproportionately decreased energy expenditure and increased appetite that occurs. These differences also suggest different therapeutic approaches may be necessary for weight loss and maintenance of reduced weight [<a href="#rid65">65</a>].</p><p>With weight loss and a reduction in fat mass, there is an accompanying reduction in circulating leptin levels which alters efferent signals from adipocytes, the gut, and endocrine organs. These physiologic responses to the maintenance of reduced weight can be mitigated or reversed by the administration of exogenous leptin and may account for the physiologic basis for the high recidivism after successful weight loss [<a href="#rid66">66</a>]. For individuals who successfully lose weight, a lifetime of committed effort to decreased energy intake and increased expenditure is required to sustain the reduced weight; the energy balance required to maintain their weight is in excess of the levels required in those who are “naturally” at the same weight. There is a strong underlying genetic basis for many of these responses as evidenced by studies of identical twin pairs to over- and underfeeding [<a href="#rid11">11,12</a>]. The net result of these homeostatic changes are changes in skeletal muscle (increased work efficiency), neuronal signaling related to energy intake (increased food reward and impulsivity, delayed satiation), and neuroendocrine function (decreased circulating concentrations of bioactive thyroid hormones and leptin). In large, longitudinal weight loss studies, different phenotypes and genotypes are correlated with weight loss or weight regain [<a href="#rid67">67,68</a>]. However, most of these genotypes are not common predictors of both weight loss and weight regain. The effects of weight loss and maintenance of reduced weight on energy homeostatic systems that favor weight regain and the greater responsiveness to leptin repletion are different  (<a class="graphic graphic_table graphicRef130720" href="/d/graphic/130720.html" rel="external">table 3</a>).<strong> </strong>Taken together, the distinct genotypes, phenotypes, and therapeutic responses to leptin indicate that different mechanisms are relevant to losing weight versus keeping it off.</p><p class="headingAnchor" id="H2178769325"><span class="h3">Physiological processes affecting energy balance</span><span class="headingEndMark"> — </span>The control of energy stores is achieved through coordinated regulation of energy intake and expenditure in response to signals from adipose, gastrointestinal, and other endocrine tissues and is integrated by the liver and elements of the central nervous system, including regulatory (hypothalamus, brain stem), hedonic/emotional (amygdala, ventral striatum, orbitofrontal cortex) and executive/restraint (cingulate, middle frontal, supramarginal, precentral, and fusiform gyri) centers. The brain processes efferent information and initiates metabolic and cognitive responses according to whether food is needed and, if so, when and where to obtain it. The brain also initiates signals that alter the metabolism of nutrients as well as the cognitive processes involved in food seeking.</p><p class="headingAnchor" id="H3037839224"><span class="h4">Energy intake</span><span class="headingEndMark"> — </span>The regulation of energy intake is essential in active weight loss and maintenance of weight loss, and there are physiologic alterations that affect this process. In studies of the National Weight Control Registry, successful maintenance of reduced body weight is associated with extremely high levels of dietary restraint [<a href="#rid69">69</a>]. Similarly, in the Look AHEAD and Diabetes Prevention Trials (DPT), dietary restraint has also been positively associated with the degree of weight loss and negatively associated with the rate of weight regain during a lifestyle intervention program among adults with type 2 diabetes or pre-diabetes [<a href="#rid70">70-74</a>].</p><p>Among weight-reduced individuals, functional magnetic resonance imaging (fMRI) demonstrates increased signalling in areas related to reward (mainly the orbitofrontal cortex) and decreased signalling in the hypothalamus and brain areas related to restraint (mainly the prefrontal cortex) in response to visual food cues [<a href="#rid75">75</a>]. These changes indicate increased hunger, delayed satiation, and decreased perception of fullness. In another study, individuals were put on a very low-calorie diet for 10 weeks and then followed throughout the remainder of the year, during which time a variety of measures were taken [<a href="#rid76">76</a>]. Hunger ratings initially fell but rebounded after the very low-calorie diet. The gastrointestinal peptide ghrelin, which stimulates appetite, increased after diet-induced weight loss; there was a decrease in other circulating mediators that inhibit intake (eg, leptin, peptide YY, cholecystokinin [CCK], pancreatic polypeptide). Further, in other studies, the changes promoting increased energy intake during and after weight loss can be partially reversed by repletion with the adipocyte-derived hormone leptin [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H1501319926"><span class="h4">Energy expenditure</span><span class="headingEndMark"> — </span>Twenty-four-hour total energy expenditure (TEE) consists of three basic components [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resting energy expenditure</strong> – The largest component is resting energy expenditure (REE), which accounts for about 60 percent of TEE and reflects cardiorespiratory work and the work of maintaining transmembrane ion gradients at rest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-resting energy expenditure</strong> – Approximately 30 percent of TEE is due to energy expended in physical activity and is known as non-resting energy expenditure (NREE) or activity energy expenditure (AEE).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thermic effect of feeding</strong> – The thermic effect of feeding (TEF), otherwise known as diet-induced thermogenesis (DIT), constitutes about 10 percent of TEE.</p><p></p><p>Maintenance of a 10 percent or greater reduction in body weight (by any individual, lean or obese) is accompanied by a highly variable (+5 to -35 percent) decline in total energy expenditure that is approximately 300 to 400 kcal/day <strong>below</strong> that predicted by the new body weight and composition; this “hypometabolism” persists in individuals successfully maintaining reduced weight for a long period of time [<a href="#rid80">80,81</a>]. A reduction in NREE accounts for the majority (approximately 150 to 250 kcal/day) of the decline in energy expenditure; the remainder is accounted for by declines in REE. Additional weight loss (&gt;10 percent) results in further declines in NREE but not REE [<a href="#rid82">82</a>]. The decline in NREE is due mainly to an approximately 20 percent increase in skeletal muscle chemomechanical contractile efficiency during low levels of energy expenditure [<a href="#rid83">83</a>]; this may have implications for the type of exercise that might be most beneficial in weight loss and/or sustaining weight loss. (See  <a class="medical medical_review" href="/d/html/5382.html" rel="external">"Obesity in adults: Behavioral therapy", section on 'Maintenance of weight loss'</a> and  <a class="medical medical_review" href="/d/html/5379.html" rel="external">"Obesity in adults: Role of physical activity and exercise"</a>.)</p><p>Of note, the hypometabolism following weight loss can be partially reversed by leptin repletion, whereas energy expenditure during weight loss appears to be unaffected [<a href="#rid66">66,78</a>].</p><p class="headingAnchor" id="H4154453427"><span class="h3">Gut microbiome</span><span class="headingEndMark"> — </span>The gut microbiome consists of approximately 100 trillion microbes that can affect the absorption and digestibility of ingested calories. Based predominantly on rodent studies demonstrating the effects of gut microbial transplant on adiposity, the composition of the gut microbiota has been hypothesized to affect both adiposity as well as the response to dietary intervention in humans. As an example, individuals with a higher versus lower gut <em>Prevotella</em> to <em>Bacteroides</em> ratio lost significantly more weight on a calorie-restricted, high-fiber diet [<a href="#rid84">84</a>]. However, there is little evidence at present to support a causal versus associative relationship between the microbiome and obesity. For example, individuals with obesity develop a microbiome similar to that of lean individuals after losing weight (with a higher <em>Firmicutes to Bacteroidetes </em>ratio), which is reversed with weight regain [<a href="#rid85">85</a>]. While there is some evidence that the gut microbiome may affect the risk of adiposity-related comorbidities such as type 2 diabetes and inflammation, there is no evidence that manipulation of the gut microbiome will be an effective obesity treatment [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H2864470206"><span class="h3">Autonomic nervous system</span><span class="headingEndMark"> — </span>Weight loss and maintenance of reduced weight provoke declines in sympathetic nervous system activity and increases in parasympathetic nervous system activity. These changes combine to reduce both REE and NREE. Decreased catecholamine excretion also inhibits the release of bioactive thyroid hormones. This decline in sympathetic nervous system tone is at least partially reversed by leptin repletion during maintenance of reduced weight but not during weight loss  (<a class="graphic graphic_table graphicRef130720" href="/d/graphic/130720.html" rel="external">table 3</a>) [<a href="#rid66">66,78</a>]. Autonomic nervous system tone may also modulate feeding behavior by effects on gut peptides such as CCK, glucagon-like peptide 1 (GLP-1), nesfatin 1, peptide YY (PYY), and pancreatic polypeptide [<a href="#rid66">66,77,87,88</a>].</p><p class="headingAnchor" id="H2318373728"><span class="h3">Neuroendocrine systems</span><span class="headingEndMark"> — </span>Weight loss and maintenance of reduced weight may both be associated with a “sick euthyroid” profile characterized by decreased circulating concentrations of bioactive thyroid hormones (triiodothyronine [T3] and thyroxine [T4]) and TSH, and increased circulating concentrations of the bioinactive reverse T3  (<a class="graphic graphic_figure graphicRef61095" href="/d/graphic/61095.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef130720" href="/d/graphic/130720.html" rel="external">table 3</a>) [<a href="#rid89">89,90</a>]. Additional studies suggest that thyroid hormone repletion after, but not during, weight loss may reverse the increased muscle efficiency that occurs as a result of weight loss [<a href="#rid91">91</a>]. Administration of leptin to weight-reduced individuals “reverses” the decline in T3 and T4 but not TSH.</p><p class="headingAnchor" id="H300122679"><span class="h3">Afferent signals from fat, the gastrointestinal tract, and endocrine organs</span><span class="headingEndMark"> — </span>The afferent signals that carry messages about nutrient surpluses or deficits include neural circuits, circulating hormones, and nutrients themselves.</p><p class="headingAnchor" id="H1922445982"><span class="h4">Adipose tissue</span><span class="headingEndMark"> — </span>Leptin, produced primarily by adipocytes, is the most potent afferent signal regulating body energy stores. During a period of stable weight, circulating concentrations of leptin are proportional to fat mass, with only a small decrease in this ratio during maintenance of reduced weight. During weight loss (negative energy balance), circulating leptin concentrations are approximately 25 to 50 percent lower than during weight maintenance at the same weight. Leptin repletion following weight loss reverses many of the metabolic and behavioral changes that oppose the maintenance of a reduced weight, while leptin administration during weight loss has only a small effect on appetite [<a href="#rid66">66</a>]. Taken together these data suggest that both leptin secretion and action are sensitive to both energy stores (fat mass) and energy balance (weight loss).</p><p class="headingAnchor" id="H3681757671"><span class="h4">Gut hormones</span><span class="headingEndMark"> — </span>Several gut hormones may be involved in regulation of food intake, including ghrelin, GLP-1, CCK, enterostatin, and peptide YY 3-36. All of these, except ghrelin, inhibit food intake. (See  <a class="medical medical_review" href="/d/html/2534.html" rel="external">"Overview of gastrointestinal peptides in health and disease"</a>.)</p><p class="headingAnchor" id="H3776655269"><span class="h5">Stimulators of food intake</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ghrelin</strong> - Ghrelin, a peptide produced in the stomach and duodenum, is an endogenous ligand for the growth hormone (GH) secretagogue receptor. This peptide has two major effects; it stimulates GH secretion and increases food intake [<a href="#rid92">92-95</a>]. Serum concentrations increase in anticipation of a meal and are suppressed by food ingestion and gastric distention. In one study, ghrelin increased GH secretion and food intake in healthy men [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">Serum ghrelin concentrations increase after diet-induced weight loss, suggesting it plays a role in the compensatory changes in appetite and energy expenditure that make maintenance of diet-induced weight loss difficult [<a href="#rid92">92</a>]. A similar increase in serum ghrelin occurs after exercise-induced weight loss (with no change in caloric intake) [<a href="#rid97">97</a>]. By contrast, in one study, gastric bypass was associated with low serum ghrelin concentrations, raising the possibility that its absence plays a role in the prolonged weight loss that often occurs after bypass [<a href="#rid92">92</a>]. However, not all studies have reported low serum ghrelin concentrations after gastric bypass [<a href="#rid98">98</a>] or after laparoscopic gastric banding [<a href="#rid99">99</a>]. Ghrelin, and the effects of bariatric surgery on ghrelin levels are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a> and  <a class="medical medical_review" href="/d/html/5380.html" rel="external">"Ghrelin", section on 'Obesity'</a> and  <a class="medical medical_review" href="/d/html/5380.html" rel="external">"Ghrelin", section on 'Gastric bypass surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropeptide Y -</strong> Neuropeptide Y is one of the most potent stimulators of food intake known. It appears to predominantly stimulate carbohydrate intake. The physiology of neuropeptide Y reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2595.html" rel="external">"Pancreatic polypeptide, peptide YY, and neuropeptide Y"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> - Melanin-concentrating hormone, GH-releasing hormone, norepinephrine, and orexin-A and orexin-B (also called hypocretin) stimulate centrally mediated drive for food intake. Like neuropeptide Y, norepinephrine appears to predominantly stimulate carbohydrate intake [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1">The importance of melanocyte-stimulating hormone (alpha-MSH) has been demonstrated by the observations that disruption of the melanocortin-4 receptor (MC4R) in the hypothalamus leads to massive obesity; the identification of an agouti-related peptide (AgRP), which may compete with the hormone; and the description of obesity caused by proopiomelanocortin (<em>POMC</em>) mutations [<a href="#rid101">101</a>]. (See <a class="local">'Melanocortin-4 receptor'</a> above and <a class="local">'Proopiomelanocortin'</a> above.)</p><p></p><p class="headingAnchor" id="H610405203"><span class="h5">Inhibitors of food intake</span><span class="headingEndMark"> — </span>A number of gut hormones inhibit food intake. However, it is often difficult to separate effects on decreasing food intake from other effects such as aversion to food [<a href="#rid101">101</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>GLP-1 released from cells in the gastrointestinal tract has an important role in glucose homeostasis and decreases hunger, increases satiety, and slows gastric emptying  (<a class="graphic graphic_table graphicRef51832" href="/d/graphic/51832.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Gastrointestinal peptides'</a> and  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy", section on 'GLP-1 receptor agonists'</a> and  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CCK decreases food intake by inducing satiety and delaying gastric emptying  (<a class="graphic graphic_table graphicRef68930" href="/d/graphic/68930.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/2558.html" rel="external">"Physiology of cholecystokinin"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic polypeptide, oxyntomodulin, and peptide YY 3-36 also suppress food intake in both lean and obese subjects. (See  <a class="medical medical_review" href="/d/html/2595.html" rel="external">"Pancreatic polypeptide, peptide YY, and neuropeptide Y"</a>.)</p><p></p><p class="headingAnchor" id="H2037232104"><span class="h4">Brain: Key modulator of body weight</span><span class="headingEndMark"> — </span>Messages reach the brain from the periphery via the circulation (eg, leptin, glucose), particularly through the more permeable blood brain barrier around the median eminence, or via vagal afferents of the autonomic nervous system. Information from the gastrointestinal tract and oropharynx is neurally transmitted to the hindbrain and processed in the nucleus of the tractus solitarius. Certain physiological states, such as pregnancy or obesity, may decrease the transport of leptin into the cerebrospinal fluid and/or decrease transduction of the leptin signal, thereby diminishing the leptin response at any given circulating leptin concentration [<a href="#rid102">102,103</a>].</p><p>In addition, several other regions in the brain are important in processing information about food in relationship to body weight, including the arcuate nucleus at the base of the hypothalamus, the paraventricular nucleus, the ventromedial and lateral hypothalamus, and selected regions of the amygdala.</p><p class="headingAnchor" id="H924223096"><span class="h3">Body fat distribution</span><span class="headingEndMark"> — </span>As with total body fat, the distribution of visceral and subcutaneous fat also has genetic determinants [<a href="#rid4">4</a>]. Gonadal steroids play a major role in determining the distribution of body fat. At the onset of puberty, males experience a decrease in fat mass and increase in lean body mass, whereas females increase their body fat relative to their muscle mass; these differences persist throughout life.</p><p>Both gonadal steroid and GH secretion decline with age. This may explain the increase in visceral fat in males with aging. Similarly, in postmenopausal females, the decline in estrogen and age-associated decrease in GH may account for the rapid increase in visceral fat.</p><p>In addition to the heritability of weight, the metabolic rate, thermic response to food, and spontaneous physical activity are, to a variable degree, heritable as well [<a href="#rid6">6</a>]. With respect to body weight, percentage of fat, fat mass, and estimated subcutaneous fat, there was approximately three times more variance among pairs than within pairs. Thus, both current weight status and the metabolic processes underlying weight gain have a strong inherited component. (See <a class="local">'Heritable factors'</a> above.)</p><p class="headingAnchor" id="H3380500739"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111344.html" rel="external">"Society guideline links: Obesity in adults"</a>.)</p><p class="headingAnchor" id="H3881485737"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15486.html" rel="external">"Patient education: Weight loss treatments (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1286383963"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic contribution to obesity</strong> – Genetic factors interact with environmental influences to produce obesity. Studies suggest that heritable factors are responsible for 40 to 75 percent of the variation in adiposity. There are many genes with polymorphisms related to obesity that have been identified by genome-wide studies  (<a class="graphic graphic_figure graphicRef87759" href="/d/graphic/87759.html" rel="external">figure 2</a>). (See <a class="local">'Heritable factors'</a> above.)</p><p></p><p class="bulletIndent1">There are a number of single-gene mutations associated with obesity, including clinical syndromes that include obesity as one of the features. (See <a class="local">'Monogenic forms of obesity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regulation of body weight and energy balance</strong> – Body weight is regulated by a feedback mechanism in which signals from adipose tissue, the gut, and endocrine organs inform the brain regarding energy stores (fat mass) and energy balance (weight gain or loss). At the body’s usual weight, energy intake and expenditure are remarkably coupled in the face of wide daily fluctuations in diet and physical activity to oppose sustained alteration in adiposity. During and after weight loss, energy intake and expenditure are uncoupled to promote weight regain via hyperphagia and hypometabolism. (See <a class="local">'The regulation of body weight'</a> above and <a class="local">'Resistance to weight loss and maintenance of reduced weight'</a> above.)</p><p></p><p class="bulletIndent1">Regulation of energy homeostasis and body weight is a complex process involving the central and autonomic nervous systems, neuroendocrine functions, gut hormones, and the leptin signaling pathway from adipocytes to the highest cortical centers of the brain. The net effect of these systems is that attempts to lose weight or sustain weight loss are met by variable changes in these systems leading to weight regain. (See <a class="local">'Physiological processes affecting energy balance'</a> above.)</p><p></p><p class="headingAnchor" id="H124120815"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George Bray, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008; 59:55.</a></li><li><a class="nounderline abstract_t">Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101:4531.</a></li><li><a class="nounderline abstract_t">Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest 2011; 121:2080.</a></li><li><a class="nounderline abstract_t">Loos RJ. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab 2012; 26:211.</a></li><li><a class="nounderline abstract_t">Wardle J, Carnell S, Haworth CM, Plomin R. Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment. Am J Clin Nutr 2008; 87:398.</a></li><li><a class="nounderline abstract_t">Pérusse L, Rankinen T, Zuberi A, et al. The human obesity gene map: the 2004 update. Obes Res 2005; 13:381.</a></li><li><a class="nounderline abstract_t">Loos RJ. The genetics of adiposity. Curr Opin Genet Dev 2018; 50:86.</a></li><li><a class="nounderline abstract_t">Robino A, Concas MP, Catamo E, Gasparini P. A Brief Review of Genetic Approaches to the Study of Food Preferences: Current Knowledge and Future Directions. Nutrients 2019; 11.</a></li><li><a class="nounderline abstract_t">Llewellyn CH, Fildes A. Behavioural Susceptibility Theory: Professor Jane Wardle and the Role of Appetite in Genetic Risk of Obesity. Curr Obes Rep 2017; 6:38.</a></li><li><a class="nounderline abstract_t">Jiang L, Penney KL, Giovannucci E, et al. A genome-wide association study of energy intake and expenditure. PLoS One 2018; 13:e0201555.</a></li><li><a class="nounderline abstract_t">Bouchard C, Tchernof A, Tremblay A. Predictors of body composition and body energy changes in response to chronic overfeeding. Int J Obes (Lond) 2014; 38:236.</a></li><li><a class="nounderline abstract_t">Bouchard C, Tremblay A. Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. J Nutr 1997; 127:943S.</a></li><li><a class="nounderline abstract_t">Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015; 518:197.</a></li><li><a class="nounderline abstract_t">Willer CJ, Speliotes EK, Loos RJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41:25.</a></li><li><a class="nounderline abstract_t">Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316:889.</a></li><li><a class="nounderline abstract_t">Loos RJ, Lindgren CM, Li S, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40:768.</a></li><li><a class="nounderline abstract_t">Thorleifsson G, Walters GB, Gudbjartsson DF, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009; 41:18.</a></li><li><a class="nounderline abstract_t">Meyre D, Delplanque J, Chèvre JC, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 2009; 41:157.</a></li><li><a class="nounderline abstract_t">Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42:937.</a></li><li><a class="nounderline abstract_t">Bradfield JP, Taal HR, Timpson NJ, et al. A genome-wide association meta-analysis identifies new childhood obesity loci. Nat Genet 2012; 44:526.</a></li><li><a class="nounderline abstract_t">Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet 2016; 387:1947.</a></li><li><a class="nounderline abstract_t">Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015; 518:187.</a></li><li><a class="nounderline abstract_t">Walter S, Mejía-Guevara I, Estrada K, et al. Association of a Genetic Risk Score With Body Mass Index Across Different Birth Cohorts. JAMA 2016; 316:63.</a></li><li><a class="nounderline abstract_t">Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007; 39:724.</a></li><li><a class="nounderline abstract_t">Gaulton KJ. Mechanisms of Type 2 Diabetes Risk Loci. Curr Diab Rep 2017; 17:72.</a></li><li><a class="nounderline abstract_t">Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007; 3:e115.</a></li><li><a class="nounderline abstract_t">Speakman JR. The 'Fat Mass and Obesity Related' (FTO) gene: Mechanisms of Impact on Obesity and Energy Balance. Curr Obes Rep 2015; 4:73.</a></li><li><a class="nounderline abstract_t">Claussnitzer M, Dankel SN, Kim KH, et al. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med 2015; 373:895.</a></li><li><a class="nounderline abstract_t">Czajkowski P, Adamska-Patruno E, Bauer W, et al. The Impact of FTO Genetic Variants on Obesity and Its Metabolic Consequences is Dependent on Daily Macronutrient Intake. Nutrients 2020; 12.</a></li><li class="breakAll">Imcivree (setmelanotide) injection, for subcutaneous use. US FDA approved product information; Rhythm Pharmaceuticals; June 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf (Accessed on June 17, 2022).</li><li><a class="nounderline abstract_t">Bonaglia MC, Ciccone R, Gimelli G, et al. Detailed phenotype-genotype study in five patients with chromosome 6q16 deletion: narrowing the critical region for Prader-Willi-like phenotype. Eur J Hum Genet 2008; 16:1443.</a></li><li><a class="nounderline abstract_t">Crinò A, Schiaffini R, Ciampalini P, et al. Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003; 162:327.</a></li><li><a class="nounderline abstract_t">Janssen S, Ramaswami G, Davis EE, et al. Mutation analysis in Bardet-Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals. Hum Genet 2011; 129:79.</a></li><li><a class="nounderline abstract_t">Marion V, Stoetzel C, Schlicht D, et al. Transient ciliogenesis involving Bardet-Biedl syndrome proteins is a fundamental characteristic of adipogenic differentiation. Proc Natl Acad Sci U S A 2009; 106:1820.</a></li><li><a class="nounderline abstract_t">Mountjoy KG. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J 2010; 428:305.</a></li><li><a class="nounderline abstract_t">Trasande L, Cronk C, Durkin M, et al. Environment and obesity in the National Children's Study. Environ Health Perspect 2009; 117:159.</a></li><li><a class="nounderline abstract_t">Dardeno TA, Chou SH, Moon HS, et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31:377.</a></li><li><a class="nounderline abstract_t">Wabitsch M, Funcke JB, Lennerz B, et al. Biologically inactive leptin and early-onset extreme obesity. N Engl J Med 2015; 372:48.</a></li><li><a class="nounderline abstract_t">Funcke JB, Moepps B, Roos J, et al. Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity. N Engl J Med 2023; 388:2253.</a></li><li><a class="nounderline abstract_t">Funcke JB, von Schnurbein J, Lennerz B, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol Cell Pediatr 2014; 1:3.</a></li><li><a class="nounderline abstract_t">Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356:237.</a></li><li><a class="nounderline abstract_t">Rosen CJ. Antagonizing the Leptin Receptor in Obesity. N Engl J Med 2023; 388:2291.</a></li><li><a class="nounderline abstract_t">Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106:271.</a></li><li><a class="nounderline abstract_t">Stijnen P, Tuand K, Varga TV, et al. The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis. Am J Epidemiol 2014; 180:1051.</a></li><li><a class="nounderline abstract_t">Lubrano-Berthelier C, Le Stunff C, Bougnères P, Vaisse C. A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans. J Clin Endocrinol Metab 2004; 89:2028.</a></li><li><a class="nounderline abstract_t">Savastano DM, Tanofsky-Kraff M, Han JC, et al. Energy intake and energy expenditure among children with polymorphisms of the melanocortin-3 receptor. Am J Clin Nutr 2009; 90:912.</a></li><li><a class="nounderline abstract_t">Jacobson P, Ukkola O, Rankinen T, et al. Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort. J Clin Endocrinol Metab 2002; 87:4442.</a></li><li><a class="nounderline abstract_t">Krude H, Biebermann H, Schnabel D, et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003; 88:4633.</a></li><li><a class="nounderline abstract_t">Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N Engl J Med 2016; 375:240.</a></li><li><a class="nounderline abstract_t">Clément K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med 2018; 24:551.</a></li><li class="breakAll">https://www.rhythmtx.com/IMCIVREE/prescribing-information.pdf (Accessed on December 08, 2020).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213793Orig1s000ltr.pdf (Accessed on December 08, 2020).</li><li><a class="nounderline abstract_t">Mendes de Oliveira E, Keogh JM, Talbot F, et al. Obesity-Associated GNAS Mutations and the Melanocortin Pathway. N Engl J Med 2021; 385:1581.</a></li><li><a class="nounderline abstract_t">Gray J, Yeo GS, Cox JJ, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006; 55:3366.</a></li><li><a class="nounderline abstract_t">Han JC, Liu QR, Jones M, et al. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 2008; 359:918.</a></li><li><a class="nounderline abstract_t">Bonnefond A, Raimondo A, Stutzmann F, et al. Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. J Clin Invest 2013; 123:3037.</a></li><li><a class="nounderline abstract_t">Silventoinen K, Konttinen H. Obesity and eating behavior from the perspective of twin and genetic research. Neurosci Biobehav Rev 2020; 109:150.</a></li><li><a class="nounderline abstract_t">Kraschnewski JL, Boan J, Esposito J, et al. Long-term weight loss maintenance in the United States. Int J Obes (Lond) 2010; 34:1644.</a></li><li><a class="nounderline abstract_t">Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353:2111.</a></li><li><a class="nounderline abstract_t">Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.</a></li><li><a class="nounderline abstract_t">Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010; 153:147.</a></li><li><a class="nounderline abstract_t">Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741.</a></li><li><a class="nounderline abstract_t">Svetkey LP, Stevens VJ, Brantley PJ, et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA 2008; 299:1139.</a></li><li><a class="nounderline abstract_t">Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014; 22:5.</a></li><li><a class="nounderline abstract_t">Aronne LJ, Hall KD, M Jakicic J, et al. Describing the Weight-Reduced State: Physiology, Behavior, and Interventions. Obesity (Silver Spring) 2021; 29 Suppl 1:S9.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Leibel RL. 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol 2014; 223:T83.</a></li><li><a class="nounderline abstract_t">Delahanty LM, Pan Q, Jablonski KA, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care 2012; 35:363.</a></li><li><a class="nounderline abstract_t">McCaffery JM, Papandonatos GD, Huggins GS, et al. FTO predicts weight regain in the Look AHEAD clinical trial. Int J Obes (Lond) 2013; 37:1545.</a></li><li><a class="nounderline abstract_t">Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82:222S.</a></li><li><a class="nounderline abstract_t">Womble LG, Williamson DA, Greenway FL, Redmann SM. Psychological and behavioral predictors of weight loss during drug treatment for obesity. Int J Obes Relat Metab Disord 2001; 25:340.</a></li><li><a class="nounderline abstract_t">Vogels N, Diepvens K, Westerterp-Plantenga MS. Predictors of long-term weight maintenance. Obes Res 2005; 13:2162.</a></li><li><a class="nounderline abstract_t">Hansen D, Astrup A, Toubro S, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord 2001; 25:496.</a></li><li><a class="nounderline abstract_t">Foster GD, Wadden TA, Swain RM, et al. The Eating Inventory in obese women: clinical correlates and relationship to weight loss. Int J Obes Relat Metab Disord 1998; 22:778.</a></li><li><a class="nounderline abstract_t">Stunkard AJ, Fernstrom MH, Price RA, et al. Weight change in depression: influence of "disinhibition" is mediated by body mass and other variables. Psychiatry Res 1991; 38:197.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Sy M, Pavlovich K, et al. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118:2583.</a></li><li><a class="nounderline abstract_t">Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365:1597.</a></li><li><a class="nounderline abstract_t">Kissileff HR, Thornton JC, Torres MI, et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr 2012; 95:309.</a></li><li><a class="nounderline abstract_t">Westerterp-Plantenga MS, Saris WH, Hukshorn CJ, Campfield LA. Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001; 74:426.</a></li><li><a class="nounderline abstract_t">Lam YY, Ravussin E. Indirect calorimetry: an indispensable tool to understand and predict obesity. Eur J Clin Nutr 2017; 71:318.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr 2008; 88:906.</a></li><li><a class="nounderline abstract_t">Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001; 21:323.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Leibel RL. Models of energy homeostasis in response to maintenance of reduced body weight. Obesity (Silver Spring) 2016; 24:1620.</a></li><li><a class="nounderline abstract_t">Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol 2010; 298:R79.</a></li><li><a class="nounderline abstract_t">Hjorth MF, Blædel T, Bendtsen LQ, et al. Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis. Int J Obes (Lond) 2019; 43:149.</a></li><li><a class="nounderline abstract_t">Mathur R, Barlow GM. Obesity and the microbiome. Expert Rev Gastroenterol Hepatol 2015; 9:1087.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Knight R, Leibel RL. The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab 2015; 26:493.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Kissileff HR, Mayer LE, et al. Energy intake in weight-reduced humans. Brain Res 2010; 1350:95.</a></li><li><a class="nounderline abstract_t">McCaffery JM, Haley AP, Sweet LH, et al. Differential functional magnetic resonance imaging response to food pictures in successful weight-loss maintainers relative to normal-weight and obese controls. Am J Clin Nutr 2009; 90:928.</a></li><li><a class="nounderline abstract_t">Liu G, Liang L, Bray GA, et al. Thyroid hormones and changes in body weight and metabolic parameters in response to weight loss diets: the POUNDS LOST trial. Int J Obes (Lond) 2017; 41:878.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr 2000; 71:1421.</a></li><li><a class="nounderline abstract_t">Rosenbaum M, Goldsmith RL, Haddad F, et al. Triiodothyronine and leptin repletion in humans similarly reverse weight-loss-induced changes in skeletal muscle. Am J Physiol Endocrinol Metab 2018; 315:E771.</a></li><li><a class="nounderline abstract_t">Koepp GA, Moore GK, Levine JA. Chair-based fidgeting and energy expenditure. BMJ Open Sport Exerc Med 2016; 2:e000152.</a></li><li><a class="nounderline abstract_t">Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623.</a></li><li><a class="nounderline abstract_t">Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908.</a></li><li><a class="nounderline abstract_t">Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992.</a></li><li><a class="nounderline abstract_t">Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005; 29:1130.</a></li><li><a class="nounderline abstract_t">Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005; 90:611.</a></li><li><a class="nounderline abstract_t">Foster-Schubert KE, McTiernan A, Frayo RS, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab 2005; 90:820.</a></li><li><a class="nounderline abstract_t">Holdstock C, Engström BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88:3177.</a></li><li><a class="nounderline abstract_t">Berthoud HR. Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 2002; 26:393.</a></li><li><a class="nounderline abstract_t">Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425.</a></li><li><a class="nounderline abstract_t">Page-Wilson G, Reitman-Ivashkov E, Meece K, et al. Cerebrospinal fluid levels of leptin, proopiomelanocortin, and agouti-related protein in human pregnancy: evidence for leptin resistance. J Clin Endocrinol Metab 2013; 98:264.</a></li><li><a class="nounderline abstract_t">Page-Wilson G, Meece K, White A, et al. Proopiomelanocortin, agouti-related protein, and leptin in human cerebrospinal fluid: correlations with body weight and adiposity. Am J Physiol Endocrinol Metab 2015; 309:E458.</a></li></ol></div><div id="topicVersionRevision">Topic 5378 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154499" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The brain, appetite, and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070752" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21633175" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetic approaches to understanding human obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498250" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genetic determinants of common obesity and their value in prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258631" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833932" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The human obesity gene map: the 2004 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29529423" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The genetics of adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31357559" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Brief Review of Genetic Approaches to the Study of Food Preferences: Current Knowledge and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28236287" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Behavioural Susceptibility Theory: Professor Jane Wardle and the Role of Appetite in Genetic Risk of Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30071075" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A genome-wide association study of energy intake and expenditure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23736367" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictors of body composition and body energy changes in response to chronic overfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164270" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673413" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic studies of body mass index yield new insights for obesity biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079261" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Six new loci associated with body mass index highlight a neuronal influence on body weight regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434869" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454148" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Common variants near MC4R are associated with fat mass, weight and risk of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079260" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19151714" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20935630" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484627" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A genome-wide association meta-analysis identifies new childhood obesity loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868660" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673412" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : New genetic loci link adipose and insulin biology to body fat distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27380344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of a Genetic Risk Score With Body Mass Index Across Different Birth Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496892" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Variation in FTO contributes to childhood obesity and severe adult obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28741265" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mechanisms of Type 2 Diabetes Risk Loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658951" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627093" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The 'Fat Mass and Obesity Related' (FTO) gene: Mechanisms of Impact on Obesity and Energy Balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287746" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33114268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The Impact of FTO Genetic Variants on Obesity and Its Metabolic Consequences is Dependent on Daily Macronutrient Intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33114268" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Impact of FTO Genetic Variants on Obesity and Its Metabolic Consequences is Dependent on Daily Macronutrient Intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648397" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detailed phenotype-genotype study in five patients with chromosome 6q16 deletion: narrowing the critical region for Prader-Willi-like phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692714" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypogonadism and pubertal development in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21052717" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutation analysis in Bardet-Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190184" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Transient ciliogenesis involving Bardet-Biedl syndrome proteins is a fundamental characteristic of adipogenic differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20504281" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Environment and obesity in the National Children's Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20600241" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Leptin in human physiology and therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25551525" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Biologically inactive leptin and early-onset extreme obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314706" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567097" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Monogenic forms of childhood obesity due to mutations in the leptin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229951" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314711" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antagonizing the Leptin Receptor in Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903343" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355447" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126516" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656839" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Energy intake and energy expenditure among children with polymorphisms of the melanocortin-3 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364415" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557433" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468060" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29736023" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29736023" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29736023" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614324" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Obesity-Associated GNAS Mutations and the Melanocortin Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130481" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753648" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Brain-derived neurotrophic factor and obesity in the WAGR syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23778136" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31959301" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Obesity and eating behavior from the perspective of twin and genetic research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479763" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term weight loss maintenance in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291981" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Randomized trial of lifestyle modification and pharmacotherapy for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246357" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679559" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17715408" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of bariatric surgery on mortality in Swedish obese subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334689" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24307184" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33759395" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Describing the Weight-Reduced State: Physiology, Behavior, and Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063755" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 20 years of leptin: role of leptin in energy homeostasis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22179955" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628854" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : FTO predicts weight regain in the Look AHEAD clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002825" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term weight loss maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319630" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Psychological and behavioral predictors of weight loss during drug treatment for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421351" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Predictors of long-term weight maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319653" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9725638" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Eating Inventory in obese women: clinical correlates and relationship to weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1754632" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Weight change in depression: influence of "disinhibition" is mediated by body mass and other variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18568078" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22029981" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term persistence of hormonal adaptations to weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22237063" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Leptin reverses declines in satiation in weight-reduced obese humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566639" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27848941" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Indirect calorimetry: an indispensable tool to understand and predict obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842775" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11375440" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful weight loss maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27460711" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Models of energy homeostasis in response to maintenance of reduced body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889869" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29777234" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26082274" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Obesity and the microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26257300" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The gut microbiota in human energy homeostasis and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595050" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Energy intake in weight-reduced humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675107" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Differential functional magnetic resonance imaging response to food pictures in successful weight-loss maintainers relative to normal-weight and obese controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28138133" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Thyroid hormones and changes in body weight and metabolic parameters in response to weight loss diets: the POUNDS LOST trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837281" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29920214" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Triiodothyronine and leptin repletion in humans similarly reverse weight-loss-induced changes in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27900194" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chair-based fidgeting and energy expenditure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023994" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11057670" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ghrelin induces adiposity in rodents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739476" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ghrelin enhances appetite and increases food intake in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917842" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ghrelin increases food intake in obese as well as lean subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699539" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585547" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Human plasma ghrelin levels increase during a one-year exercise program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843162" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12204189" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Multiple neural systems controlling food intake and body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7984236" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Positional cloning of the mouse obese gene and its human homologue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118421" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cerebrospinal fluid levels of leptin, proopiomelanocortin, and agouti-related protein in human pregnancy: evidence for leptin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26152765" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Proopiomelanocortin, agouti-related protein, and leptin in human cerebrospinal fluid: correlations with body weight and adiposity.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
